In the Claims

Claims 1 - 13 (Cancelled)

- 14. (Original) A method of manufacturing an ASIC1a channel blocker comprising the steps of:
 - (a) obtain at least one Psalmopoeus cambridgei spider;
 - (b) obtaining venom from said spider by electrically milking said spider;
 - (c) separating toxins of said venom by reversed-phase chromatography;
 - (d) further separating components of said venom by cation exchange chromatography;
 - (e) recovering and isolating separated toxins of said venom; and
- (f) combining said isolated toxin with a pharmaceutically acceptable carrier such that the toxin is capable of functioning as an ASIC1a channel blocker.
- 15. (Original) A substantially pure polypeptide functioning as an ASIC1a channel blocker and comprising the following amino acid sequence:

EDCIPKWKGCVNRHGDCCEGLECWKRRRSFEVCVPKTPKT and pharmaceutically-acceptable salts thereof.

16. (Original) The substantially pure polypeptide defined in Claim 15 comprising the following amino acid sequence:

EDCIPKWKGCVNRHGDCCEGLECWKRRRSFEVCVPKTPKT.

- 17. (Original) The substantially pure polypeptide as defined in Claim 15, wherein the polypeptide has a calculated molecular weight of about 4689.
- 18. (Original) A substantially pure compound comprising the following amino acid sequence:

EDCIPKWKGCVNRHGDCCEGLECWKRRRSFEVCVPKTPKT.

19. (Original) A peptide isolated from the venom of the *Psalmopoeus cambridgei* spider and comprising the following amino acid sequence:

EDCIPKWKGCVNRHGDCCEGLECWKRRRSFEVCVPKTPKT.

20. (Original) A pharmaceutical composition containing a polypeptide comprising the following amino acid sequence:

EDCIPKWKGCVNRHGDCCEGLECWKRRRSFEVCVPKTPKT or pharmaceutically-acceptable salts thereof and a pharmaceutically-acceptable carrier.

- 21. (Original) A composition functioning as an ASIC1a channel blocker comprising at least one toxin extracted from the *Psalmopoeus cambridgei* spider, said at least one toxin being capable of functioning as an ASIC1a channel blocker.
- 22. (Original) A composition as defined in Claim 15, wherein the effets of said at least one toxin are reversible.
- 23. (New) A substantially pure polypeptide functioning as an ASIC1a channel blocker extracted from venom of South American tarantula *Psalmopoeus cambridgei*.
- 24. (New) A substantially pure polypeptide functioning as an ASIC1a channel blocker having a calculated molecular weight of about 4689 Da.
- 25. (New) A substantially pure polypeptide functioning as an ASIC1a channel blocker comprising an amino acid sequence represented by SEQ ID No. 1 and pharmaceutically-acceptable salts thereof.